Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $23.0152W HIGH $47.40
Volume
3.03 K
Value Traded
2.34 M
Short % Float
3.01%
-1.07%Week
+2.7%1 Month
-39.1%3 Month
+15.26%6 Month
+286.45%5 Year
+843.7%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
233.29 M
EPS (TTM)
1.35
P/E Ratio
20.58
Ent. Value
212.13 M
Total Shares
8.37 M
Float Shares
6.87 M
Insiders
17.05%
Institutions
59.82%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ELMD Catalyst Timeline
Dated clinical, regulatory and corporate events for Electromed, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Electromed, Inc.
2Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Past FDA Catalysts and PDUFA Decisions
How ELMD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Electromed, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every ELMD program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Nagel Bradley M.Officer (Chief Financial Officer) | Disposition | -674 18,964 held | $42.30 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ELMD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ELMD for Q2 2026. | ||||
ELMD Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ELMD ranks across every disease it competes in
Competitive Position is a premium feature
See how ELMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialELMD News
ELMDElectromed, Inc. to Participate in the H.C. Wainwright 28th Annual Global Investment Conference and LD Micro 20th Annual Main Event
Electromed, Inc. has announced its participation in two key investment conferences: the H.C. Wainwright 28th Annual Global Investment Conference and the LD Micro 20th Annual Main Event. This involvement highlights the company's commitment to engaging with investors and enhancing its market presence. Such events are crucial for networking and showcasing company developments.
Read more →ELMD▼ -19.2%on this news
Electromed Announces CEO’s Planned Retirement
Electromed, Inc. announced that CEO Jim Cunniff plans to retire on or about April 2, 2027. Cunniff has led the company since 2023, overseeing significant revenue growth and operational improvements. The Board of Directors will conduct a national search for his successor, engaging an executive search firm to assist in the process. Cunniff expressed his commitment to ensuring a smooth transition.
Read more →ELMD▼ -19.2%on this news
Electromed, Inc. Announces Record Fiscal 2026 Fourth Quarter and Full Year Financial Results
Electromed, Inc. has announced its record financial results for the fourth quarter and full year of fiscal 2026. The company showcased significant growth, reflecting its strong market position and operational success. This announcement underscores Electromed's commitment to delivering value and performance in the biopharma sector.
Read more →ELMDElectromed, Inc. Announces Share Repurchase
Electromed, Inc. has authorized a share repurchase program for up to $5.0 million, aimed at enhancing shareholder value. The company's management believes using excess cash for stock buybacks is a prudent decision that will maintain strong financial performance while allowing for future investments. The actual timing and amount of repurchases will depend on market conditions, with the board noting the potential risks involved in forward-looking statements regarding the company's financial position.
Read more →ELMDElectromed, Inc. Announces Record Financial Performance in Fiscal 2025 Second Quarter
Electromed, Inc. reported record financial results for the second quarter of fiscal 2025, with net revenues rising 18.7% to $16.3 million compared to the same period last year. The company's impressive performance was driven by increases in referrals and efficiencies in its direct-to-patient model. Operating income also reached a record $2.5 million, highlighting effective cost management along with revenue growth. Electromed continues to invest in strategic initiatives to enhance productivity and operational efficiency.
Read more →ELMDElectromed, Inc. Announces Fiscal 2025 First Quarter Financial Results Electromed delivers eighth consecutive quarter of year-over-year revenue and profit growth, while continuing to invest in strategic growth initiative
Electromed, Inc. announced its financial results for the first quarter of fiscal 2025, ending September 30, 2024, demonstrating strong performance with a 19% year-over-year revenue growth to $14.7 million. The company’s profit also increased significantly, reaching $11.5 million, attributed to higher sales and efficiencies in operations. Additionally, Electromed continues to expand its sales force and territories and launched a new marketing campaign to enhance its bronchiectasis treatment offerings. The overall financial health is solid, with no debt and a cash reserve of $13.9 million.
Read more →ELMDElectromed, Inc. Announces Share Repurchase Authorization NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. ("Electromed") (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced
Electromed, Inc. has announced a new share repurchase authorization of up to $5 million, effective September 11, 2024. This decision follows the exhaustion of a previous repurchase program and is supported by the company's recent record performance in fiscal 2024. The management has emphasized strong revenue growth and profitability, which contributes to significant free cash flow. This strategic move reflects the board's confidence in the company's future growth and intent to enhance shareholder value.
Read more →ELMD▲ +6.9%on this news
Electromed, Inc. Announces Record Fiscal Year 2024 Financial Results Record Q4 and full year financial results NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. ("Electromed") (NYSE American: ELMD), a leader in innov
Electromed, Inc. reported record financial results for fiscal year 2024, with total revenues increasing by 13.8% to $54.7 million. The company also saw a significant increase in operating income and net income per share, driven by growth in its direct homecare and hospital markets. Despite challenges such as the expiration of the CMS waiver, Electromed continued to invest in growth and gained market share throughout the year. The company aims to build on this momentum as it prepares for fiscal year 2025.
Read more →ELMDInvestor Presentation Electromed, Inc. Investor Presentation August 2024 NYSE American: ELMD Innovation Leader in Airway Clearance Technologies | 2 Investor Presentation Forward Looking Statements Certain statements in
Electromed, Inc. (NYSE American: ELMD) presented its investor overview for August 2024, emphasizing its position as an innovation leader in airway clearance technologies. The company reported strong financial metrics and an expanding market for its SmartVest airway clearance system. Forward-looking statements indicate that while there are significant growth opportunities, uncertainties exist, particularly related to regulatory compliance and market competition. Electromed is focused on enhancing market penetration and improving sales channels for its products.
Read more →ELMDElectromed, Inc. Announces Record Revenue in Fiscal 2024 Third Quarter Growth initiatives drive record revenue NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. ("Electromed") (NYSE American: ELMD), a leader in innov
Electromed, Inc. reported record revenues of $13.9 million for the third quarter of fiscal 2024, marking a 14.9% increase from the previous year. Operating income also rose significantly to $1.493 million, reflecting solid performance and strategic growth initiatives. The company continues to enhance its sales force, which has contributed to robust profitability and efficiency in service delivery. With a strong cash position and no debt, Electromed aims to maintain this positive momentum into the final quarter of the fiscal year.
Read more →ELMDElectromed, Inc. Announces Record Financial Performance in Fiscal 2024 Second Quarter Growth initiatives drive record revenue, improve margins and enhance operational efficiency NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Elect
Electromed, Inc. (ELMD) reported record financial performance for the second quarter of fiscal 2024, with revenue increasing 17% to $13.7 million compared to the previous year. The operating income also reached a record high of $2.263 million, accounting for 16.5% of total revenue. The results were attributed to a growth in sales territories and improved efficiencies in the reimbursement process. Electromed continues to invest in its product offerings and customer service, aiming for sustained market growth in the coming quarters.
Read more →ELMD▼ -7.9%on this news
Electromed, Inc. Announces Fiscal 2024 First Quarter Financial Results NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. ("Electromed" or the "Company") (NYSE American: ELMD), a leader in innovative airway clearance
Electromed, Inc. reported financial results for the first quarter of fiscal 2024, highlighting a 16% increase in net revenue to $12.3 million compared to the same period last year. The growth was attributed to higher referrals, approvals, and reimbursement rates across all revenue categories, including homecare, hospital, and international. The company's gross profit reached $9.5 million, although gross margin decreased slightly due to rising costs. Operating income improved to $142,000, and net income rose to $155,000, reflecting overall successful operational execution.
Read more →ELMD▲ +6.5%on this news· ran to +18% by day 1
Electromed, Inc. Announces Fiscal 2023 Fourth Quarter and Full Year Financial Results --Record Annual Revenue -- -- Fourth Quarter Revenue Increased 21% Year-Over-Year; Full Year Revenue Increased 15% -- NEW PRAGUE, Minn
Electromed, Inc. announced its financial results for the fourth quarter and the fiscal year ending June 30, 2023. The company achieved record revenues of $13.6 million for Q4, marking a 21% year-over-year increase, and an overall revenue increase of 15% to over $48 million for the fiscal year. Despite navigating difficulties such as the expiration of the CMS waiver and supply chain disruptions, Electromed launched its next-generation SmartVest Clearway device. Moving into FY 2024, the management plans to focus on sales force expansion and enhancing marketing strategies to support growth in the bronchiectasis treatment market.
Read more →ELMDElectromed Names Jim Cunniff as President and Chief Executive Officer Healthcare Executive Brings More Than 30 Years of Executive Experience and Commercial Success to Electromed NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Elect
Electromed, a leader in airway clearance technologies, has appointed Jim Cunniff as its new President and Chief Executive Officer, effective July 1, 2023. Cunniff brings over 30 years of executive experience in the MedTech and healthcare sectors, having successfully led organizations like Provista and Stryker Corporation. He succeeds Kathleen Skarvan, who will continue as Chair of the Board after a decade of significant leadership at the company.
Read more →ELMDElectromed, Inc. Announces Fiscal 2023 Third Quarter Results Quarterly Net Revenue Increase of 19% Year-over-Year NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. ("Electromed") (NYSE American: ELMD), a leader in in
Electromed, Inc. announced its fiscal 2023 third quarter financial results, reporting a 19% year-over-year increase in net revenue, totaling $12.1 million. The revenue growth was attributed to a rise in referrals and improved sales team productivity. The company noted that their new SmartVest Clearway product has been well-received, contributing positively to their market position. However, they also recognized challenges such as increased material costs and temporary supply chain disruptions.
Read more →ELMDElectromed, Inc. Announces Fiscal 2023 Second Quarter Results Growth initiatives help drive record quarterly revenue NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. ("Electromed") (NYSE American: ELMD), a leader in
Electromed, Inc. announced strong financial results for the second quarter of fiscal year 2023, reporting a record revenue of $11.7 million, up 14.5% year-over-year. The company attributes this growth to expanded sales efforts and successful new product releases, notably the SmartVest Clearway, which has received positive feedback from patients. However, it faced challenges with rising material and shipping costs, which impacted its gross profit margin. Additionally, Electromed experienced a decline in international revenue by 41.9% compared to the previous year.
Read more →ELMDElectromed, Inc. Announces Fiscal 2023 First Quarter Results Continued Momentum on Key Growth Initiatives NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. ("Electromed" or the "Company") (NYSE American: ELMD), a lea
Electromed, Inc. Announces Fiscal 2023 First Quarter Results Continued Momentum on Key Growth Initiatives NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. ("Electromed" or the "Company") (NYSE American: ELMD), a leader in innovative airway clearance technologies, today a
Read more →ELMDElectromed, Inc. Appoints Brad Nagel as Chief Financial Officer Accomplished medical device leader to fill key strategic role NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. ("Electromed" or the "Company") (NYSE Am
Electromed, Inc. Appoints Brad Nagel as Chief Financial Officer Accomplished medical device leader to fill key strategic role NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. ("Electromed" or the "Company") (NYSE American: ELMD), a leader in innovative airway clearance
Read more →ELMDElectromed, Inc. Announces Fiscal 2022 Fourth Quarter and Full Year Financial Results --Record Annual Revenue and Growth Rate -- Fourth Quarter Revenue Increased 19% Year-Over-Year; Full Year Revenue Increased 16.5% -- L
Inc. Announces Fiscal 2022 Fourth Quarter and Full Year Financial Results Annual Revenue and Growth Rate Fourth Quarter Revenue Increased 19% Year-Over-Year; Full Year Revenue Increased 16.5% -- Leveraging Strategic Investments to Accelerate Growth -- PRAGUE, Minn.--(BUSINESS
Read more →ELMDElectromed, Inc. Announces Election of Andrew Summers as Additional Independent Director Electromed Also Enters into New Cooperation Agreement with Summers Value Partners and Expands Board to Eight Members Mr. Summers to
Inc. Announces Election of Andrew Summers as Additional Independent Director Also Enters into New Cooperation Agreement with Summers Value Partners and Expands Board to Eight Members Summers to serve as Vice Chair of the Finance and Strategy Committee PRAGUE, Minn., July 25, 2
Read more →About Electromed, Inc.
Headquarters500 SIXTH AVENUE NW, NEW PRAGUE, MN, 56071
Founded2010
BIOPHARMAWATCH ELITE PLUS
Trade the next ELMD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime